SCHEMBL20123069

SCHEMBL20123069

Clc1cc(-c2ccc(Cl)nc2)c2c(c1)c1ccncc1n2CC1CCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 3/20 0.39
DYRK1A Q13627 2/20 0.39
ROCK2 O75116 1/20 0.39
PTGER4 P35408 1/20 0.37
NFATC1 O95644 1/20 0.36
GSK3B P49841 1/20 0.36
METAP2 P50579 1/20 0.35
CRHR1 P34998 1/20 0.35
IDO1 P14902 1/20 0.34
CDK4 P11802 1/20 0.34
CDK6 Q00534 1/20 0.34
EGLN1 Q9GZT9 2/20 0.34
KDM4C Q9H3R0 3/20 0.33
SLC34A1 Q06495 1/20 0.32
CYP2A6 P11509 1/20 0.32
HRH1 P35367 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
GRIN1 Q05586 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30664277 1.00 KCNH2 (0.39) KCNH2DYRK1AROCK2PTGER4NFATC1
SCHEMBL20122885 0.85 KCNH2 (0.49) KCNH2DYRK1AROCK2PTGER4NFATC1
SCHEMBL30664200 0.85 KCNH2 (0.49) KCNH2DYRK1AROCK2PTGER4NFATC1
SCHEMBL30664155 0.83 ROCK2 (0.45) KCNH2DYRK1AROCK2PTGER4NFATC1
SCHEMBL20122876 0.83 ROCK2 (0.45) KCNH2DYRK1AROCK2PTGER4NFATC1
SCHEMBL20122943 0.83 ROCK2 (0.40) DYRK1AROCK2PTGER4METAP2CYP2A6
SCHEMBL30664240 0.83 ROCK2 (0.40) DYRK1AROCK2PTGER4METAP2CYP2A6
SCHEMBL20122886 0.82 DYRK1A (0.46) KCNH2DYRK1AROCK2PTGER4NFATC1
SCHEMBL20122983 0.81 METAP2 (0.44) ROCK2METAP2
SCHEMBL30664139 0.81 METAP2 (0.44) ROCK2METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 KCNH2 3028/4885DYRK1A 493/4885ROCK2 1093/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 KCNH2 3028/4885DYRK1A 493/4885ROCK2 1093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.